Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Anticancer Research|September 26, 2025
Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial CarcinomaKyosuke Nishio, Kensuke Hirosuna, Taizo Uchimoto, et al.
Japanese Journal of Clinical Oncology|February 3, 2026
Age-stratified clinical outcomes and adverse events in patients with metastatic castration-sensitive prostate cancer receiving triplet therapy with darolutamide, androgen deprivation therapy, and docetaxelTaizo Uchimoto, Kensuke Hirosuna, Heima Niigawa, et al.
Clinical Genitourinary Cancer|October 25, 2023
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective StudyTakuhisa Nukaya, Kiyoshi Takahara, Atsuhiko Yoshizawa, et al.
World Journal of Urology|November 4, 2023
Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinomaTakuya Tsujino, Kazumasa Komura, Teruo Inamoto, et al.
The Prostate|March 15, 2026
The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line ARPI TherapyTakeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, et al.
Oncology|October 15, 2023
Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver MetastasesKyosuke Nishio, Takuya Higashio, Kazumasa Komura, et al.
Japanese Journal of Clinical Oncology|October 19, 2025
Prognostic impact of lung metastasis in patients treated with androgen receptor signaling inhibitors for castration-sensitive prostate cancer: data from the ULTRA-Japan ConsortiumTaizo Uchimoto, Kensuke Hirosuna, Heima Niigawa, et al.
Japanese Journal of Clinical Oncology|March 12, 2026
Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysisKazuki Nishimura, Kensuke Hirosuna, Heima Niigawa, et al.
Targeted Oncology|May 28, 2024
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial CarcinomaTaizo Uchimoto, Takuya Matsuda, Kazumasa Komura, et al.
World Journal of Urology|February 24, 2025
Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's impactTatsuo Fukushima, Takuya Tsujino, Moritoshi Sakamoto, et al.
Pageof 9